Miscarriage, Recurrent
Conditions
Brief summary
To compare the abv3-integrin expression in endometrium tissue among RIF women between the GnRH analogue with Aromatase Inhibitor (Group A) , GnRH analogue with progesterone (Group B) and GnRH analogue alone as control group (Group C)
Detailed description
i. To determine the abv3-integrin expression isolated from endometrium tissue from women with RIF prior to medical therapy. ii. To determine the abv3-integrin expression isolated from endometrium tissue from Group A, Group B and Group C following the medical therapy. iii. To compare the abv3-integrin expression from endometrium tissue obtained from Group A, B and C following the medical therapy. iv. To compare the implantation rates among Group A, B and C following the medical therapy. v. To compare the ongoing pregnancy among Group A, B and C following the medical therapy
Interventions
DRUGGNRH Analoge, Duphaston, Letrozole
GNRH Analoge, Duphaston, Letrozole
Sponsors
Universiti Kebangsaan Malaysia Medical Centre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
All recruited women will be allocated in three groups, and endometrial tissue sampling will be obtained prior to medical intervention assigned during luteal phase depending on their menstrual cycle. All these women will be divided randomly in three groups A, B & C equally by using the auto-randomized program in SPSS version 21.0.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Women of 18 to 40 years of age * No significant pre-existing major medical. * Diagnosed as recurrent implantation failure - at least two or more failure of achieving pregnancy following embryo transfer (ET) despite the optimum endometrial thickness and good quality of embryo (unexplained). * Regular menstrual cycle atleast 3 months prior to treatment * Not taking any hormonal treatment for atlest 3months prior to recruitment * Agreed to participate
Exclusion criteria
* Concurrent significant pre-existing major medical conditions such as uncontrolled diabetes, active systemic lupus erythematosus (SLE) or Anti Phospholipid Syndrome (APS) that will interfere with implantation. * Poor quality of embryo * Suboptimal endometrial thickness(\<8mm) during the embryo transfer (ET). * On hormonal therapy prior to recruitment. * Not agreed to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| endometrial abv3-integrin expression expressions | 12 months | pre and post treatment endometrial abv3-integrin expressions |
Countries
Malaysia
Outcome results
None listed